Edesa Biotech, Inc. (EDSA)

Edesa Biotech announced positive Phase 3 results for paridiprubart (EB05) in treating ARDS, reporting its Fiscal 3rd and 2nd Quarter 2025 Results, and announced a Chief Financial Officer transition. The company also announced a $15.0 Million Private Placement Priced At-the-Market. EDSA stock has experienced a decline of -9.52% over the last six months, and a -36.19% fall in the last month.

Demand for Edesa Biotech's ARDS treatments, such as EB05, could be influenced by seasonal outbreaks of respiratory illnesses. EDSA stock has some monthly seasonality, with July having the highest probability of a positive return and June having the lowest.

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases. The company's pipeline includes EB05 for ARDS, EB01 for Allergic Contact Dermatitis, EB06 for vitiligo, EB07 for pulmonary fibrosis, and EB02 for hemorrhoids. Edesa Biotech develops host-directed therapeutics that modulate the body's immune response and explores alternatives to steroids and JAK inhibitors.

Edesa Biotech, Inc. is headquartered in Markham, Ontario, Canada, and serves global markets through strategic alliances in North America, Europe, and Asia.

Information explicitly detailing Edesa Biotech, Inc.'s brand reputation is not readily available. Investor sentiment, as indicated by Stocktwits, shows whether users are generally bullish or bearish on the stock, reflecting investor perception rather than a broader brand reputation among the public or medical community.

Edesa Biotech is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 40.96% of the company is owned by institutional shareholders, and 129.79% by Edesa Biotech insiders. Major institutional owners include Stonepine Capital Management, LLC, Rubric Capital Management LP, and Vanguard Group Inc. The largest individual shareholder is Pardeep Nijhawan, who owns 5.94 million shares, representing 84.56% of the company.